Category: PRESS RELEASES

20
March 2019
Enterome announces research collaboration with renowned US Cancer Institute focused on new microbiome-derived cancer immunotherapy
Read more
23
October 2018
Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease
Read more
02
August 2018
Enterome CEO to present at two upcoming investor conferences in the United States
Read more
20
June 2018
Enterome to participate in the 2018 Microbiome Movement – Drug Development Summit in Boston
Read more
04
June 2018
Enterome to attend the Jefferies 2018 Global Healthcare Conference in New York
Read more
01
June 2018
Enterome to Feature Promising Phase 1 clinical data with its Lead Candidate EB8018 for Crohn’s Disease at the Digestive Disease Week 2018
Read more
04
January 2018
Enterome raises €32 million ($38.5 million) in a Series D financing
Read more
27
October 2017
Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers
Read more
20
September 2017
Enterome to Move its Research Laboratories to Genopole, France’s First Biocluster
Read more

Enterome

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Email: info@enterome.com
Metro Station: Ledru-Rollin (Line 8)